



## **Embera NeuroTherapeutics to Present at the 19<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference**

BOSTON, Mass. and SHREVEPORT, La. – August 31, 2017 – [Embera NeuroTherapeutics, Inc.](#), a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that Robert (Bob) Linke, the Company’s President and Chief Executive Officer, and Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will provide a corporate update at the 19<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference. The presentation will be on Monday, September 11, 2017 at 9:35 a.m. Eastern time. The conference is being held from September 10-12, 2017 at Lotte New York Palace Hotel in New York, New York.

### **About Embera NeuroTherapeutics**

Embera NeuroTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on treating a broad range of addictions where the major clinical challenge is a limited range of effective therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions related to stress responses that drive craving and relapse associated with these disorders. Embera is advancing EMB-001 development programs in cocaine use disorder and smoking cessation. [www.emberaneuro.com](http://www.emberaneuro.com)

### **Contacts**

Bob Linke, President and CEO  
Embera NeuroTherapeutics, Inc.  
617-719-9406  
[rlinke@emberaneuro.com](mailto:rlinke@emberaneuro.com)

### For Media:

Kari Watson  
MacDougall Biomedical Communications  
781-235-3060  
[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)